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Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired immune-
mediated disease of the peripheral nervous system, either being isolated or associated with
other systemic diseases, most frequently with lymphoproliferative subtypes.1 CIDP concurrent
with monoclonal gammopathy of undetermined significance (MGUS) accounts for up to
20%–30% of all cases,2 is often considered clinically indistinguishable from typical CIDP, and
responds similarly to immunologic therapies.3 CIDP clinical course may be poorly responsive
to conventional immunologic or chemotherapy treatment.4 Consequently, allogeneic and
autologous hematopoietic stem cell transplantations (HSCTs) have been proposed in selected
cases.5 To our knowledge, only a single patient with concurrent IgG lambda MGUS has been
treated with autologous HSCT,6 and no case of IgG kappa MGUS is reported so far.
Clinical case
A previously healthy 49-year-old male patient presented with a 4-week history of progressive
muscle weakness, gait ataxia, perioral paresthesias, and subjective swallowing difficulties.
Neurologic examination revealed normal cranial nerves—proximal rather than distal paresis
with diffusely absent reflexes and mild lower limb sensory deficiencies. CSF analysis showed
increased protein (1,185 mg/L) and normal cell count. Electrophysiologic nerve conduction
studies disclosed findings of demyelinating polyneuropathy (table e-1, links.lww.com/NXI/
A313); needle electromyographic examination in the arms and legs was normal. Serum VEGF
concentration was also normal (134 pg/mL). Nerve ultrasound and spinal MRI showed diffuse
hypertrophic, hyperechogenic nerves (figure e-1, links.lww.com/NXI/A312).
Figure 1 illustrates the clinical course and therapy schedule.
CIDP was diagnosed according to European Federation of Neurological Societies/Peripheral
Nerve Society criteria,7 although a sural nerve biopsy was not deemed necessary.
Bone marrow aspirate smears and trephine biopsy demonstrated IgG kappa MGUS with 4%
kappa light chain–restricted plasma cells (table e-2, links.lww.com/NXI/A314). There was no
evidence of amyloidosis or other hematologic malignancies on whole body CT scan and bone
marrow biopsy. Fluorescence in-situ hybridization (FISH) revealed no cytogenetic abnor-
malities, and CRAB criteria (elevated calcium level, renal failure, anemia, and bone lesions)
were not met.
In July 2013, walking distance was less than 20 m with a cane, and the patient developed
respiratory distress necessitating mechanical respiratory support. High-dose chemotherapy
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with melphalan, followed by autologous HSCT together with
continued IV immunoglobulin (IVIG) therapy were admin-
istered as salvage therapy (figure 1).
Conditioning treatment was melphalan (200 mg/m2 IV).
Stem cell mobilization for autologous HSCTs was performed
by vinorelbine (35 mg/m2 IV) and G-CSF (10 μg/kg body
weight). A total of 3.2 × 106 CD34+ cells/kg b.w. were
transfused at the day 0 of autologous HSCT. The patient fully
recovered and resumed his professional activities (figure 1).
The free-serum light chain ratio and the previously sup-
pressed lambda light chains normalized (table e-2, links.lww.
com/NXI/A314).
Two years after HSCT, the patient presented with a clinical
relapse. Bone marrow analysis was again compatible with IgG
kappa MGUS with 4% kappa light-chain restricted plasma
cells (table e-2, links.lww.com/NXI/A314). Chromosome
Figure Clinical course of neurologic symptoms according to CDAS and treatment strategies at presentation and at relapse
(A) Timeline and relationship between neurologic symptoms according to CDAS and treatment strategies at presentation. CDAS score 5 represent unstable
active disease with abnormal examination and progressive course (5A treatment <3months, 5C on treatment). Score 4: improvement >3months, <1 year (4A
with normal examination, 4B with abnormal examination). Score 3: stable active disease >1 year (3A with normal examination, 3B with abnormal exami-
nation). Score 2: remission <5 years, off treatment (2A with normal examination, 2B with abnormal examination). Score 1 cure >5 years, off treatment. (B)
Timeline and relationship between treatment and neurologic symptoms according to CDAS at relapse. IVIG, high-dose immunoglobulin: symbol represent
IVIG treatment cycles:d 0.4 g/kg (35 g),Δ 1.0 g/kg (85 g),♦ 2 g/kg (160 g); blue line: steroids; green line: AZA; purple line:MM; red triangle (▼): RTX; orange: PEX;
blue: IMA; green line fine: LEN; red arrow (↓): autologous HSCT;ᴥ preventive hematopoietic stem cell mobilization and collection. AZA = azathioprine; CDAS =
CIDP disease activity status; HSCT = hematopoietic stem cell transplantation; IMA = immunoabsorption; IVIG = IV immunoglobulin; LEN = lenalidomide; MM =
mycophenolate mofetil; PEX = plasmapheresis; RTX = rituximab.
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banding analysis and FISH at that time identified monosomy
13q14.3 and t (11;14). Despite IVIG, the neurologic symptoms
worsened, and a second autologous HSCTwas performed after
conditioning with melphalan (200 mg/m2 IV) preceded by 2
cycles of lenalidomide (25 mg/d on a 21‐days cycle) and ste-
roids. Neurologic symptoms completely resolved within weeks
(figure 1). Continuous maintenance therapy with lenalidomide
10 mg/d on 21‐days cycles was started. Three years after the
second HSCT, the patient was still asymptomatic.
Discussion
We describe a strong and timely correlation between 2
HSCTs and the resolution of the CIDP-related neurologic
symptoms. Particularly at relapse, when the second HSCT
was performed immediately after clinical aggravation, clinical
improvement was prompt. Neurologic improvement was
closely correlated with the rebalance of the serum free light
chains after both HSCTs. The mechanism of HSCT-induced
CIDP remission is not yet defined. Based on the normaliza-
tion of the serum-free light chains kappa and lambda re-
garding absolute values and ratio after both HSCTs, we
speculate that it may be attributed to the regression of the
immune-mediated mechanisms related to the shrinking
MGUS clone.
Our report confirms the positive impact of melphalan con-
ditioning preceding autologous HSCT in patients with
MGUS-associated neurologic disorders.
The favorable outcome of our approach at relapsing empha-
sizes to further explore adding lenalidomide for induction and
post-transplant maintenance therapy in case of CIDP and
concurrent IgG kappa MGUS. Our report may as well suggest
to investigate other novel myeloma-specific therapeutic ap-
proaches in clinically refractory CIDP with concurrent
MGUS, e.g., the anti-CD38 antibody daratumumab and
venetoclax, a selective, orally bioavailable B-cell lymphoma 2
inhibitor that induces cell death in multiple myeloma cells,
particularly in those harboring t(11;14), that express high
levels of B-cell lymphoma 2 relative to B-cell lymphoma-extra
large and myeloid leukemia cell 1.
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